Manufacturer & developer of cancer diagnostic technologies and products. The company is a biotechnology company, which engages in the development, manufacture, marketing, distribution, and licensing of cancer diagnostic technologies and products. Its products include NMP22 Test Kit and NMP22 BladderChek Test, which are designed to detect the presence of a specific protein marker in urine correlated with the presence of bladder cancer. Its research and development programs include NMP179 program, a nuclear matrix protein associated with cervical cancer and cervical precancerous conditions; NMP66 program to develop a blood-based test for breast cancer; NMP48 program for prostate cancer; and NMP35, a colon cancer program. In addition, it sells allergy and other diagnostic products manufactured by others. The company sells its products directly to physicians, hospitals, clinics, and physician office laboratories in the United States and Germany, as well as to distributors in other parts of Europe.